Cite
Severino M, Sivasaravanaparan M, Olesen LØ, et al. Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine. Alzheimers Dement (N Y). 2018;4:215-223doi: 10.1016/j.trci.2018.04.005.
Severino, M., Sivasaravanaparan, M., Olesen, L. �. �., von Linstow, C. U., Metaxas, A., Bouzinova, E. V., Khan, A. M., Lambertsen, K. L., Babcock, A. A., Gramsbergen, J. B., Wiborg, O., & Finsen, B. (2018). Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine. Alzheimer's & dementia (New York, N. Y.), 4215-223. https://doi.org/10.1016/j.trci.2018.04.005
Severino, Maurizio, et al. "Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine." Alzheimer's & dementia (New York, N. Y.) vol. 4 (2018): 215-223. doi: https://doi.org/10.1016/j.trci.2018.04.005
Severino M, Sivasaravanaparan M, Olesen LØ, von Linstow CU, Metaxas A, Bouzinova EV, Khan AM, Lambertsen KL, Babcock AA, Gramsbergen JB, Wiborg O, Finsen B. Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine. Alzheimers Dement (N Y). 2018 May 24;4:215-223. doi: 10.1016/j.trci.2018.04.005. eCollection 2018. PMID: 29955664; PMCID: PMC6021554.
Copy
Download .nbib